News

Showing posts for — Author: kioradev

10.26.21

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline WALTHAM, MA, October 26, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical...
Eye Exam
09.09.21

EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, MA, September 9, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that...
09.08.21

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers -Trial remains on track with topline data expected in Q4 2021- WALTHAM,...
08.12.21

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, MA, August 12, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a...
08.10.21

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, MA, August 10, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a...
07.26.21

EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- WALTHAM, MA, July 26, 2021 – EyeGate...
05.12.21

EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- - OBG: U.S. IND submission and initiation of Phase...
04.01.21

EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

WALTHAM, MA, April 01, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it...